Article: Nippon Shinyaku, Apogepha Terminate Development of NS-8, for the Treatment of Overactive Bladder

Article: Nippon Shinyaku and Roche Terminate NS-220 ...
JCNN News Summaries - Japan Corporate News Network;  December 18, 2006 ;     323 words ... ... 2006 - (JCN) - Nippon Shinyaku Co., Ltd. announced ... License Agreement on Nippon Shinyaku's new investigational drug, NS-220, for the ... pharmaceuticals division. NS-220 is a novel agent discovered by Nippon Shinyaku and was licensed ...

Article: Nippon Shinyaku, INNOVIVE Pharmaceuticals Conclude ...
JCNN News Summaries - Japan Corporate News Network;  January 6, 2006 ;     310 words ... ... Tokyo, Jan 6, 2006 - (JCN) - Nippon Shinyaku announced on January 5 that it ... exclusively develop and market NS-187, a drug candidate developed by Nippon Shinyaku, worldwide except in Japan. NS-187, which is a molecular targeted ...

Article: IDEC Pharmaceuticals and Nippon Shinyaku Sign ...
Business Wire;  September 30, 2002 ;     700+ words ... ... clinical studies. NS Pharma, Inc ... subsidiary of Nippon Shinyaku, is conducting ... gastrointestinal fields. Nippon Shinyaku is marketing an ... field in Japan. NS Pharma, Inc ... subsidiary of Nippon Shinyaku, was established ...

Article: Abbott and Nippon Shinyaku to Collaborate on ...
PR Newswire;  October 12, 1998 ;     700+ words ... ... to develop and market Nippon Shinyaku's drug NS-49 for urinary stress ... effects. We believe NS-49 has the potential ... quality of life." "Nippon Shinyaku is pleased to work with ... development and marketing of NS-49. Their experience ...

Article: IDEC, JAPAN'S NIPPON SHINYAKU SIGN DEAL ON ...
AsiaPulse News;  October 7, 2002 ;     519 words ... ... Pharmaceuticals Corporation and Nippon Shinyaku Co., Ltd. have signed ... known as HMN-214. Nippon Shinyaku has granted IDEC a worldwide ... clinical studies. NS Pharma, Inc., a U.S. subsidiary of Nippon Shinyaku, is conducting Phase ...

Article: Studies from Nippon Shinyaku Co., Ltd. provide new ...
Biotech Week;  November 5, 2008 ;     700+ words ... ... wrote K. Kuwano and colleagues, Nippon Shinyaku Co., Ltd.. The researchers concluded: "NS-304 is a promising alternative ... information, contact K. Kuwano, Nippon Shinyaku Co. Ltd, Discovery Research Laboratories ...

Article: Roche and Nippon Shinyaku sign deal.
Pharma Marketletter;  November 3, 2003 ;     422 words ...Roche and Japan's Nippon Shinyaku have entered a collaboration to ... drug candidate in this program, NS-220, is a peroxisome proliferator ... arising from the collaboration. Nippon Shinyaku will have rights to co-develop ...